Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track GILD with free AI briefings, catalyst countdowns, and dilution alerts.

GILD · GILEAD SCIENCES, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$6.4B Cash on Hand
CF+ Cash Runway
1.7% Short Interest
$175.92 Analyst Target (26)
Follow GILD by email Get an email when GILD reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about GILD, unsubscribe in one click. Privacy

💊 Upcoming FDA Decisions

PDUFA DateDrugIndicationTypePoAOptions-implied move
2026-12-23 anito-cel relapsed or refractory multiple myeloma BLA 61% ±9% by Dec 24

Options-implied move = price of the at-the-money straddle for the first option expiry after the PDUFA date, as a share of the stock price (Yahoo Finance quotes, Nov 17). It prices every move until that expiry, not only the FDA decision.

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →

📣 What GILD Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Cobicistat
FDA approved Sep 2014 · Tybost (discontinued)
HIV-1-infection Phase 4 · NCT06337032 Recruiting
Emtricitabine And Tenofovir Alafenamide
FDA approved Apr 2016 · Descovy
HIV-1-infection Phase 4 · NCT06337032 Recruiting
Lenacapavir
FDA approved Dec 2022 · Sunlenca
HIV-1 Infection Phase 4 · NCT07908446 Not yet recruiting
Sofosbuvir
FDA approved Dec 2013 · Sovaldi
HIV - Human Immunodeficiency Virus Phase 4 · NCT07560046 Not yet recruiting
Emtricitabine And Tenofovir Disoproxil Fumarate
FDA approved Aug 2004 · Truvada
Pre-Exposure Prophylaxis of HIV Infection Phase 3 · NCT04994509 Active not recruiting
Tenofovir Disoproxil Fumarate
FDA approved Oct 2001 · Viread
Pre-Exposure Prophylaxis of HIV Infection Phase 3 · NCT04994509 Active not recruiting
Seladelpar
FDA approved Aug 2024 · Livdelzi
Primary Biliary Cholangitis Phase 3 · NCT06051617 Recruiting
3rd ARV Agent HIV-1-infection Phase 4 · NCT06337032 Recruiting
Nibrin HIV-1-infection Phase 4 · NCT06337032 Recruiting
Cancer-Associated Fibroblast HIV-1-infection Phase 4 · NCT06337032 Recruiting
Imidazole Mustard HIV-1 Infection Phase 4 · NCT07908446 Not yet recruiting
Bictegravir HIV -1 Infection Phase 4 · NCT07476339 Recruiting
DRV HIV-1-infection Phase 4 · NCT06337032 Recruiting
Elvitegravir, Cobicistat, Emtricitabine, And… HIV-1-infection Phase 4 · NCT06337032 Recruiting
E/C/F/TAF HIV-1-infection Phase 4 · NCT06337032 Recruiting
F/TAF HIV-1-infection Phase 4 · NCT06337032 Recruiting

Also used in these trials (approved or third-party drugs, not GILD's own candidates): Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate, Capecitabine, Lurbinectedin, Paclitaxel, Pembrolizumab, Topotecan, Abemaciclib, Atezolizumab, Bevacizumab, Carboplatin, Empagliflozin, Fluorouracil.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

GILD holds $6.4B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 15 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GILD files for a raise →

👥 Who Owns GILD

Insiders 0.3% Institutions (3174 holders) 91.4% Public and other holders 8.3%
HolderTypeShares% of sharesAs of
Blackrock Inc. Institution (13F) 125,246,865 10.10% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 93,327,127 7.52% 2026-03-31
FMR LLC Institution (13G, 5%+) 65,539,477 5.28% 2025-12-31
State Street Corporation Institution (13F) 60,954,967 4.91% 2026-09-30
Invesco Ltd. Institution (13F) 38,662,436 3.12% 2026-09-30
Capital World Investors Institution (13F) 35,929,833 2.90% 2026-09-30
Vanguard Portfolio Management LLC Institution (13F) 35,685,818 2.88% 2026-09-30
Geode Capital Management, LLC Institution (13F) 30,190,640 2.43% 2026-09-30
Price (T.Rowe) Associates Inc Institution (13F) 27,664,121 2.23% 2026-09-30
Capital Research Global Investors Institution (13F) 23,980,766 1.93% 2026-09-30
GILEAD SCIENCES, INC.
10% owner · +40.38M options
Insider 2,879,996 0.23% 2026-10-30
Daniel Patrick O'Day
Chairman & CEO, Director · +334,365 options
Insider 551,683 0.04% 2026-11-04

Share count 1,240,338,614 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-12
filed 2026-11-16
Kramer Kelly A.
Option exercise (M) 10,376 $66.92 11,715
2026-11-12
filed 2026-11-16
Kramer Kelly A.
Sale (S) 1,676 $168.23 10,039
2026-11-12
filed 2026-11-16
Kramer Kelly A.
Sale (S) 3,800 $169.44 6,239
2026-11-12
filed 2026-11-16
Kramer Kelly A.
Sale (S) 4,700 $170.49 1,539
2026-11-12
filed 2026-11-16
Kramer Kelly A.
Sale (S) 200 $171.44 1,339

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full GILD picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GILD and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.